Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma

Conclusion: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity.

Source: In Vivo - August 30, 2020 Category: Research Authors: OHASHI, Y., YATABE, M., NIIJIMA, D., TANI, K., OGAWA, C., YACHI, Y., KAGOO, T., BOKU, S., UENO, H., YANO, T., HIGAI, K., YOKOYAMA, A. Tags: Clinical Studies Source Type: research